Literature DB >> 9066364

Use of desferrioxamine in the treatment of aceruloplasminemia.

H Miyajima1, Y Takahashi, T Kamata, H Shimizu, N Sakai, J D Gitlin.   

Abstract

Aceruloplasminemia is a newly recognized autosomal recessive disorder of iron metabolism resulting in neurodegeneration of the retina and basal ganglia. We report here on the treatment of a patient who developed progressive extrapyramidal symptoms that included blepharospasm, grimacing, and rigidity associated with increased iron deposition in the brain and visceral organs. Treatment for 10 months with the iron chelator desferrioxamine decreased brain iron stores, prevented progression of the neurological symptoms, and reduced plasma lipid peroxidation. These data suggest that early treatment with this chelator may be useful in such patients to diminish central nervous system iron accumulation and to prevent or ameliorate neurological symptoms associated with neurodegeneration.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9066364     DOI: 10.1002/ana.410410318

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  30 in total

Review 1.  The emerging role of iron dyshomeostasis in the mitochondrial decay of aging.

Authors:  Jinze Xu; Emanuele Marzetti; Arnold Y Seo; Jae-Sung Kim; Tomas A Prolla; Christiaan Leeuwenburgh
Journal:  Mech Ageing Dev       Date:  2010-04-29       Impact factor: 5.432

2.  Extrapyramidal and cerebellar movement disorder in association with heterozygous ceruloplasmin gene mutation.

Authors:  Jens Kuhn; Hiroaki Miyajima; Yoshitomo Takahashi; Bernhard Kunath; Ursula Hartmann-Klosterkoetter; Déirdre Cooper-Mahkorn; Mark Schaefer; Heiko Bewermeyer
Journal:  J Neurol       Date:  2005-01       Impact factor: 4.849

3.  Aceruloplasminemia: a case report.

Authors:  Domenico Di Raimondo; Antonio Pinto; Antonino Tuttolomondo; Paola Fernandez; Clara Camaschella; Giuseppe Licata
Journal:  Intern Emerg Med       Date:  2008-04-12       Impact factor: 3.397

Review 4.  Aceruloplasminaemia: a rare but important cause of iron overload.

Authors:  Adam Doyle; Ferry Rusli; Prithi Bhathal
Journal:  BMJ Case Rep       Date:  2015-05-14

Review 5.  The role of iron in brain ageing and neurodegenerative disorders.

Authors:  Roberta J Ward; Fabio A Zucca; Jeff H Duyn; Robert R Crichton; Luigi Zecca
Journal:  Lancet Neurol       Date:  2014-10       Impact factor: 44.182

Review 6.  Drug Repurposing in Parkinson's Disease.

Authors:  Dilan Athauda; Thomas Foltynie
Journal:  CNS Drugs       Date:  2018-08       Impact factor: 5.749

7.  Cisplatin binds human copper chaperone Atox1 and promotes unfolding in vitro.

Authors:  Maria E Palm; Christoph F Weise; Christina Lundin; Gunnar Wingsle; Yvonne Nygren; Erik Björn; Peter Naredi; Magnus Wolf-Watz; Pernilla Wittung-Stafshede
Journal:  Proc Natl Acad Sci U S A       Date:  2011-04-11       Impact factor: 11.205

8.  Iron chelation therapy in aceruloplasminaemia: study of a patient with a novel missense mutation.

Authors:  R Mariani; C Arosio; S Pelucchi; M Grisoli; A Piga; P Trombini; A Piperno
Journal:  Gut       Date:  2004-05       Impact factor: 23.059

9.  Desferrioxamine in warm reperfusion media decreases liver injury aggravated by cold storage.

Authors:  Peter G Arthur; Xian-Wa Niu; Wen-Hua Huang; Bastiaan Deboer; Ching Tat Lai; Enrico Rossi; John Joseph; Gary P Jeffrey
Journal:  World J Gastroenterol       Date:  2013-02-07       Impact factor: 5.742

Review 10.  Neuroprotective strategies in Parkinson's disease : an update on progress.

Authors:  Silvia Mandel; Edna Grünblatt; Peter Riederer; Manfred Gerlach; Yona Levites; Moussa B H Youdim
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.